Evren Technologies

What Evren Technologies does

Evren Technologies, Inc. is a privately-held medical device company founded in 2018 and headquartered in Newberry, Florida, near the University of Florida. The company develops non-invasive, wearable bioelectronic neuromodulation devices based on transcutaneous auricular Vagus Nerve Stimulation (taVNS), with a core focus on treating post-traumatic stress disorder (PTSD). Its flagship consumer device, the Phoenix 100, is a discreet earbud-style wearable that delivers mild electrical stimulation to the auricular vagus nerve to regulate the autonomic nervous system, while a mobile app and proprietary closed-loop algorithm adjust stimulation intensity in response to the user's physiological state. A second product, the Phoenix CR, is a programmable research system launched in August 2023 with physiological monitoring, data logging, and remote communication, sold directly to academic and clinical investigators conducting taVNS studies.

The technology is grounded in Stephen Porges' Polyvagal Theory and is built on a licensed University of Florida patent covering closed-loop tVNS, co-invented by the company's founding scientists. Evren's IP portfolio includes a registered U.S. trademark for "Phoenix" covering neurostimulation for psychological disorders, including PTSD and other indications. The company has secured FDA Breakthrough Device Designation (July 2021) and acceptance into the FDA's Pilot TAP Program (September 2024), positioning the Phoenix 100 for a De Novo classification pathway targeting the broader U.S. PTSD treatment market.

Commercially, Evren is pre-revenue on a therapy basis, with its only product revenue coming from low-volume Phoenix CR research device sales. The company has raised roughly $422K in non-dilutive funding through an NIH SBIR Phase I award and a DoD military contract, alongside a Regulation Crowdfunding campaign on StartEngine targeting up to $5M from retail investors. The customer base spans military veterans with PTSD (primary), first responders, sexual assault survivors, patients with comorbid mild traumatic brain injury, and clinical researchers using Phoenix CR. Distinction between the investigational device and any future commercial launch is clearly disclosed on the company website, and distribution for the eventual commercial Phoenix 100 is planned via direct enterprise sales to healthcare providers, including VA hospitals and clinical institutions, pending FDA clearance.

Name

Evren Technologies

Legal name

Evren Technologies, Inc.

Website

https://evrenvns.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Evren Technologies is a privately-held Florida medical device company founded in 2018 that develops non-invasive, wearable earbud devices using transcutaneous auricular Vagus Nerve Stimulation (taVNS) to treat PTSD in military veterans, first responders, and trauma survivors, with both a research SKU and an FDA-designated commercial product in development.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

akta.pro secondary industries

Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)

Keywords

• Wearable medical devices
• Vagus nerve stimulation
• PTSD treatment
• Neuromodulation therapy
• Bioelectronic medicine

Headquarters

HQ city

Florida

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Phoenix CR Research Device Sales: Sale of Phoenix CR research devices to taVNS researchers conducting clinical trials. Launched in July 2023, this represents the company's first product revenue.
2. Phoenix 100 Commercial Device (Pending FDA): Commercial sale of Phoenix 100 patient-facing device pending FDA De Novo classification. Not yet generating revenue as device is still in clinical trials.
3. Government Grants (NIH/DoD): Non-dilutive funding from NIH SBIR Phase I awards and DoD military contracts supporting R&D activities. Over $250,000 NIH funding, $172K military contract, nearly $500K total awarded.
4. Equity Crowdfunding: Regulation Crowdfunding via StartEngine platform raising capital from retail investors with minimum $499 investment.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Evren Technologies develops and sells the Phoenix neuromodulation platform, a non-invasive wearable earbud medical device that delivers transcutaneous auricular vagus nerve stimulation (taVNS) to treat PTSD. The Phoenix CR programmable research system is currently sold directly to clinical researchers, while the Phoenix 100 commercial device is pending FDA De Novo classification for healthcare provider distribution. Both products are based on Polyvagal Theory and incorporate a proprietary closed-loop algorithm with physiological monitoring.

Product overview

Evren Technologies offers two main products in its Phoenix neuromodulation platform: the Phoenix 100 (clinical/commercial target product) and Phoenix CR (research device). The Phoenix 100 is a non-invasive wearable earbud delivering transcutaneous auricular vagus nerve stimulation (taVNS) to treat PTSD by regulating the autonomic nervous system. The Phoenix CR-100 is a programmable research tool launched in 2023 for clinical trials, featuring physiological monitoring, data logging, and home study capability. Both products are controlled via a mobile app that tracks PTSD symptoms and adjusts stimulation through a proprietary algorithm.

Differentiator

Problem solved

Functional benefit

Brands

• Phoenix 100: Non-invasive wearable earbud device delivering transcutaneous auricular vagus nerve stimulation (taVNS) for PTSD treatment. FDA Breakthrough Device Designation granted.
• Phoenix CR
• Phoenix Laboratory

Products and services

• Phoenix 100 Non-invasive wearable earbud device delivering transcutaneous auricular vagus nerve stimulation (taVNS) to treat PTSD. Delivers a light electrical tingle to activate the vagus nerve, helping regulate the sympathetic and parasympathetic nervous systems to reduce PTSD symptoms. Pending FDA De Novo classification for commercial sale to healthcare providers and VA hospitals.
• Phoenix CR (CR-100) Research System Programmable taVNS research tool designed for clinical trials and laboratory use. Features physiological monitoring to ensure stimulation quality, data logging, remote communication capabilities, wide amplitude and frequency choices, usage tracking, adherence monitoring, and home study capability. Sold directly to taVNS researchers and clinical institutions conducting studies on PTSD, TBI, anxiety, depression, and sleep disruption.

Quantifiable outcome

• 92% of pilot study participants experienced a decrease in PTSD symptoms
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• University of FloridacoreStrategic or Co-development PartnerFounding scientists Dr. Damon G. Lamb, Dr. Eric Porges, and Dr. John Williamson are faculty members at University of Florida. The company has deep research collaboration with UF researchers on taVNS for PTSD treatment. Evren is headquartered near UF. Technology originated from UF research.
• Emory UniversitycoreStrategic or Co-development PartnerPartnership with Emory University and Dr. Doug Bremner for military contract supporting soldier safety and performance. Dr. Bremner serves on Evren's Scientific Advisory Board and is a leading PTSD researcher and authority on acute stress at Emory.
• Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development PartnerDr. Adrienne Boire, Assistant Member in Human Oncology and Pathogenesis Program, serves on Evren's Scientific Advisory Board.
• SlideWave, LLCcoreTechnology or IntegrationPartnership with SlideWave for design and development of mobile app controller for Phoenix device. Focus on user-centric design for FDA compliant medical devices. SlideWave develops HIPAA compliant systems and has experience with medical device software.
• UCSF Rosenman InstitutecoreImplementation/ SI/ Consulting PartnerSelected as 2021 Rosenman Innovators cohort, receiving customized coaching in communications, product development, IP, clinical/regulatory, reimbursement, marketing, and business strategy from network of experts.
• MedTech InnovatorcoreImplementation/ SI/ Consulting PartnerSelected for showcase and accelerator program with access to leading manufacturers, providers, investors, and industry stakeholders. Up to $500,000 in cash and in-kind prizes available through competition.
• StartEnginecoreChannel Partner/ Reseller/ DistributorRegulation Crowdfunding platform for raising capital from retail investors. StartEngine is a leading equity crowdfunding platform in the US with over 760,000 prospective investors.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• NeuroPace: NeuroPace markets the RNS System, a closed-loop responsive neurostimulator for epilepsy. Its closed-loop architecture is conceptually analogous to Evren's proprietary closed-loop taVNS, and it represents a comparable closed-loop neuromodulation business.
• LivaNova: LivaNova markets the industry's leading implantable Vagus Nerve Stimulation (VNS Therapy) system for epilepsy and treatment-resistant depression. As an established incumbent in clinical VNS, it is a benchmark and potential strategic acquirer of any non-invasive tVNS entrant.
• Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems (Evoke) with physiological feedback. It is a relevant neuromodulation peer with a similar closed-loop, sensing-based architecture to Phoenix.
• Medtronic: Medtronic operates in implantable VNS, deep brain stimulation, and other neuromodulation franchises. It is a broad incumbent relevant to Evren's positioning and a likely strategic acquirer of differentiated neuromodulation IP.

Direct peers

• Parasym: Parasym develops a transcutaneous auricular vagus nerve stimulation (taVNS) device marketed for stress, sleep, and mental wellness use cases. It is a direct competitor in the consumer/clinician tVNS category that Evren targets with Phoenix 100.
• Cala Health: Cala Health builds wearable neuromodulation devices (Cala Trio for essential tremor, Cala kIQ for Parkinson's tremor) using non-invasive peripheral nerve stimulation. It is a comparable wearable, prescription-grade neuromodulation business model.
• Soterix Medical: Soterix is a leading manufacturer of tVNS/transcutaneous VNS research and clinical devices used across PTSD, depression, and neurorehabilitation studies. It directly competes with Evren's Phoenix CR research channel.
• Electrocore (now Axonic Therapies): Electrocore markets gammaCore, a non-invasive vagus nerve stimulation device, and is the most direct commercial competitor to Evren's Phoenix taVNS platform. Both companies target non-invasive auricular/cervical VNS in home and clinical settings.

Emerging players

• Cognito Therapeutics: Cognito Therapeutics is developing gamma sensory stimulation for Alzheimer's disease, representing an emerging non-invasive neuromodulation modality that overlaps thematically with Evren's neurostimulation platform approach.
• Big Health: Big Health markets Sleepio and Daylight, FDA-cleared digital therapeutics for insomnia and anxiety, with growing PTSD/trauma applications. It is an emerging non-pharmacological competitor in the broader PTSD and trauma-related symptom space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/evrenvns
• YouTubeyoutube.com/@evrentechnologies7471/videos
• Facebookfacebook.com/EvrenVNS
• LinkedInlinkedin.com/company/evren-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evren Technologies